Research progress and therapeutic prospects of visfatin in tumor immunity
10.12354/j.issn.1000-8179.2025.20250647
- VernacularTitle:内脂素在肿瘤免疫中的研究进展与治疗前景
- Author:
Liu SHIQI
1
;
Bai JUNYI
1
;
Feng XINYU
1
;
Wang YINGMEI
1
;
Xue FENGXIA
1
Author Information
1. 天津医科大学总医院妇产科,天津市女性生殖健康与优生重点实验室(天津市 300052)
- Publication Type:Journal Article
- Keywords:
visfatin;
immunity;
tumor;
NAMPT inhibitor(NAMPTi)
- From:
Chinese Journal of Clinical Oncology
2025;52(10):533-538
- CountryChina
- Language:Chinese
-
Abstract:
Visfatin,also known as nicotinamide phosphoribosyl transferase(NAMPT)or pre-B-cell colony-enhancing factor,is a proinflam-matory adipokine.Its immunomodulatory effects are closely associated with its pro-inflammatory activity,influencing the secretion of vari-ous cytokines and the function of immune cells.Visfatin exerts pro-tumorigenic effects in most cancers.The tumor immune microenviron-ment(TIME)comprises immune cells within the tumor tissue and an array of secreted cytokines.Growing evidence suggests that visfatin plays a regulatory role in the TIME by promoting inflammatory responses and modulating the polarization of immune cells,their secretory functions,surface protein expression,and energy metabolism,thereby influencing cancer progression.These newly discovered mechanisms provide a critical foundation for the application of NAMPT inhibitors(NAMPTi)in cancer immunotherapy.This review summarizes recent ad-vances in understanding the role of visfatin in tumor immunology and explores the therapeutic potential of NAMPTi in oncology.
